Last reviewed · How we verify
rhASA - Dose Level 2
At a glance
| Generic name | rhASA - Dose Level 2 |
|---|---|
| Also known as | HGT-1111, metazym |
| Sponsor | Shire |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Metazym for the Treatment of Patients With Late Infantile Metachromatic Leukodystrophy (MLD) (PHASE1)
- Long-term Metazym Treatment of Patients With Late Infantile Metachromatic Leukodystrophy (MLD) (PHASE1, PHASE2)
- Multicenter Study of HGT-1110 Administered Intrathecally in Children With Metachromatic Leukodystrophy (MLD) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- rhASA - Dose Level 2 CI brief — competitive landscape report
- rhASA - Dose Level 2 updates RSS · CI watch RSS
- Shire portfolio CI